Device Trial Radar · NCT01219218
Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris
Last checked: Nov 19, 2026Latest source record: Feb 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jan 2009
Primary completion
Jan 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- MedispecNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Academisch Ziekenhuis Maastricht
- First posted
- Oct 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.
Conditions
- Refractory Angina Pectoris
Interventions
Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)Device
Energy Density - 0.09 mJ/mm2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to AnginaTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.